**Lisinopril or Carvedilol for Cardiotoxicity**

**Trial design:** Patients with breast cancer undergoing trastuzumab chemotherapy were randomized to lisinopril vs. carvedilol vs. placebo. They were followed for 12 months.

**Results**

- Decrease in left ventricular ejection fraction (LVEF) >10%: 30% of the lisinopril group vs. 29% of the carvedilol group vs. 32% of the placebo group (p = not significant)
- Among those who received an anthracycline, decrease in LVEF >10%: 37% of the lisinopril group vs. 31% of the carvedilol group vs. 47% of the placebo group (p = 0.009)

**Conclusions**

- Among patients with breast cancer undergoing chemotherapy with trastuzumab, neither lisinopril nor carvedilol was effective at preventing cardiomyopathy compared with placebo.

Presented by Dr. Maya Guglin at ACC 2018